Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 6/2017

01.06.2017 | Cardio-oncology (EH Yang, Section Editor)

Cancer as a Risk Factor for Cardiovascular Disease

verfasst von: Dana Elena Giza, Gloria Iliescu, Saamir Hassan, Konstantinos Marmagkiolis, Cezar Iliescu

Erschienen in: Current Oncology Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Improvements in early diagnosis and cancer treatments have contributed to high survival rates for many cancer patients. However, these patients often die of cardiovascular disease rather than recurrence of their cancer. Heart disease manifesting after cancer may be due to several mechanisms: shared cardiovascular risks between cancer and cardiovascular disease, inflammatory states associated with malignancies, and/or cardiotoxic effects of cancer therapy. Cancer treatment increases the risk of cardiovascular diseases directly by damaging critical structures of the heart or indirectly by promoting accelerated atherosclerosis. Estimating cardiovascular risk by using advanced imaging and monitoring of the cardiac biomarkers can be used for early detection and treatment of subclinical cardiac injury. Better knowledge of these early and late cardiac effects in cancer patients will enable adoption of both primary and secondary prevention measures of long-term treatment complications in cancer survivors.
Literatur
1.
Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41.CrossRefPubMed
2.
•• Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013;7(2):253–61. We consider the paper of Weaver et al. important as is one of the early articles published on CVD risk factors in cancers survivors, which might be overlooked and may compromise long-term health and well-being.CrossRefPubMedPubMedCentral
3.
4.
Aleman BM, Moser EC, Nuver J, et al. Cardiovascular disease after cancer therapy. EJC supplements : EJC: official journal of EORTC, European Organization for Research and Treatment of Cancer … [et al]. 2014;12(1):18–28.
5.
• Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32(7):900–7. We consider this paper important because it provides evidence that smoking, obesity, poor diet, and inactivity can affect oncological outcomes and lead to increased cancer mortality is cancer survivors.CrossRefPubMed
6.
7.
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27–32.PubMed
8.
Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375–80.CrossRefPubMedPubMedCentral
9.
Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–81.CrossRefPubMedPubMedCentral
10.
11.
Goncalves I, den Ruijter H, Nahrendorf M, Pasterkamp G. Detecting the vulnerable plaque in patients. J Intern Med. 2015;278(5):520–30.CrossRefPubMed
12.
Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46(6):937–54.CrossRefPubMed
13.
Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004;110(3):278–84.CrossRefPubMed
14.
Eckert J, Schmidt M, Magedanz A, Voigtlander T, Schmermund A. Coronary CT angiography in managing atherosclerosis. Int J Mol Sci. 2015;16(2):3740–56.CrossRefPubMedPubMedCentral
15.
•• Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122–31. We consider this paper important because it provides new insights on the cardiotoxicity of anticancer agents that can lead to significant complications that can affect patients treated for various malignancies. In this article, commonly used chemotherapy agents, including several recently approved medications, for their propensity to cause cardiotoxicity are reviewed.CrossRefPubMed
16.
Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.CrossRefPubMed
17.
Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.CrossRefPubMed
18.
Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21(Suppl 7):vii 173–9.
19.
Moudgil R, Yeh ET. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond. Can J Cardiol. 2016;32(7):863–870.e865.CrossRefPubMed
20.
Vejpongsa P, Yeh ET. Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95(1):45–52.CrossRefPubMed
21.
Sudhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15(4):661–4.CrossRefPubMed
22.
Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348–51.CrossRefPubMed
23.
Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303–7.CrossRefPubMed
24.
Lim SH, Wilson SM, Hunter A, Hill J, Beale P. Takotsubo cardiomyopathy and 5-fluorouracil: getting to the heart of the matter. Case Rep Oncol Med. 2013;2013:206765.PubMedPubMedCentral
25.
Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287–97.CrossRefPubMed
26.
Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9.CrossRefPubMed
27.
Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610–1.CrossRefPubMed
28.
Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075–88.CrossRefPubMedPubMedCentral
29.
Stevens PL, Lenihan DJ. Cardiotoxicity due to chemotherapy: the role of biomarkers. Curr Cardiol Rep. 2015;17(7):603.CrossRefPubMed
30.
Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys. 2007;67(1):10–8.CrossRefPubMed
31.
Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656–65.CrossRefPubMedPubMedCentral
32.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.CrossRefPubMed
33.
Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008;5(11):655–67.CrossRefPubMed
34.
Fajardo LF, Stewart JR. Coronary artery disease after radiation. N Engl J Med. 1972;286(23):1265–6.PubMed
35.
van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–17.CrossRefPubMed
36.
Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(8):2625–31.CrossRef
37.
McEniery PT, Dorosti K, Schiavone WA, Pedrick TJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987;60(13):1020–4.CrossRefPubMed
38.
Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(1):43–9.CrossRef
39.
Shimizu Y, Kodama K, Nishi N, et al. Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950–2003. BMJ. 2010;340:b 5349.CrossRef
40.
Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270(16):1949–55.CrossRefPubMed
41.
Boekel NB, Schaapveld M, Gietema JA, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys. 2016;94(5):1061–72.CrossRefPubMed
42.
Iliescu CA, Grines CL, Herrmann J, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv. 2016;87(5):E202–23.CrossRefPubMed
43.
Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300, 000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557–65.CrossRefPubMed
44.
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443–50.CrossRefPubMed
45.
Krone RJ. Managing coronary artery disease in the cancer patient. Prog Cardiovasc Dis. 2010;53(2):149–56.CrossRefPubMed
46.
De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.CrossRefPubMed
47.
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016;152(5):1243–75.CrossRefPubMed
48.
Carrozza Jr JP, Kuntz RE, Levine MJ, et al. Angiographic and clinical outcome of intracoronary stenting: immediate and long-term results from a large single-center experience. J Am Coll Cardiol. 1992;20(2):328–37.CrossRefPubMed
49.
Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91(6):1676–88.CrossRefPubMed
50.
Mueller C, Roskamm H, Neumann FJ, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol. 2003;41(6):969–73.CrossRefPubMed
51.
Gross CM, Posch MG, Geier C, et al. Subacute coronary stent thrombosis in cancer patients. J Am Coll Cardiol. 2008;51(12):1232–3.CrossRefPubMed
52.
Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(16):3718–25.CrossRef
53.
Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia—from the St. Jude Lifetime Cohort. Br J Haematol. 2014;165(3):364–74.CrossRefPubMedPubMedCentral
54.
Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol. 2012;35(5):504–9.CrossRefPubMed
55.
Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–103.CrossRefPubMed
56.
Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938–45.CrossRefPubMed
57.
Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology. Clin Chem Lab Med. 2011;49(12):1937–48.CrossRefPubMed
58.
Newby LK, Ohman EM. Biomarkers: troponin testing—risk stratification to stratified medicine. Nat Rev Cardiol. 2015;12(11):625–6.CrossRefPubMed
59.
Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(10):1042–9.CrossRef
60.
Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(25):3910–6.CrossRef
61.
D’Errico MP, Grimaldi L, Petruzzelli MF, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):e239–46.CrossRefPubMed
62.
Burgdorf C, Nef HM, Haghi D, Kurowski V, Radke PW. Tako-tsubo (stress-induced) cardiomyopathy and cancer. Ann Intern Med. 2010;152(12):830–1.CrossRefPubMed
63.
Akashi YJ, Goldstein DS, Barbaro G, Ueyama T. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation. 2008;118(25):2754–62.CrossRefPubMedPubMedCentral
64.
van de Donk NW, America YG, Zelissen PM, Hamer BJ. Takotsubo cardiomyopathy following radioiodine therapy for toxic multinodular goitre. Neth J Med. 2009;67(10):350–2.
65.
Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag. 2008;4(6):1367–70.CrossRefPubMedPubMedCentral
66.
Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013;9(2):233–42. x CrossRefPubMed
67.
Lee S, Lim SP, Yu JH, et al. Stress-induced cardiomyopathy during pulmonary resection (Takotsubo syndrome)—a case report. Korean J Thorac Cardiovasc Surg. 2011;44(4):294–7.CrossRefPubMedPubMedCentral
68.
Gianni M, Dentali F, Lonn E. 5 Flourouracil-induced apical ballooning syndrome: a case report. Blood Coagul Fibrinolysis. 2009;20(4):306–8.CrossRefPubMed
69.
Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4.CrossRefPubMedPubMedCentral
70.
Grunwald MR, Howie L, Diaz Jr LA. Takotsubo cardiomyopathy and fluorouracil: case report and review of the literature. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(2):e11–4.CrossRef
71.
Munoz E, Iliescu G, Vejpongsa P, et al. Takotsubo stress cardiomyopathy: “good news” in cancer patients? J Am Coll Cardiol. 2016;68(10):1143–4.CrossRefPubMed
Metadaten
Titel
Cancer as a Risk Factor for Cardiovascular Disease
verfasst von
Dana Elena Giza
Gloria Iliescu
Saamir Hassan
Konstantinos Marmagkiolis
Cezar Iliescu
Publikationsdatum
01.06.2017
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 6/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0601-x

Weitere Artikel der Ausgabe 6/2017

Current Oncology Reports 6/2017 Zur Ausgabe

Hot Topic

Cost-Effectiveness of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: a Critical Review

Lung Cancer (JM Johnson, Section Editor)

Telemedicine and Palliative Care: an Increasing Role in Supportive Oncology

Gastrointestinal Cancers (J Meyer, Section Editor)

Update on Embolization Therapies for Hepatocellular Carcinoma

Lymphomas (MR Smith, Section Editor)

Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma

Neuro-oncology (S Nagpal, Section Editor)

Immune Checkpoint Inhibitors for Brain Metastases

Cardio-oncology (EH Yang, Section Editor)

The Role of Biomarkers in Detection of Cardio-toxicity

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise